Esperion Therapeutics (ESPR) Competitors $1.00 0.00 (-0.34%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.99 0.00 (-0.17%) As of 04/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. WVE, COLL, ELVN, DYN, GPCR, CMRX, ETNB, CDMO, RCUS, and VIRShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Chimerix (CMRX), 89bio (ETNB), Avid Bioservices (CDMO), Arcus Biosciences (RCUS), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Dyne Therapeutics Structure Therapeutics Chimerix 89bio Avid Bioservices Arcus Biosciences Vir Biotechnology Wave Life Sciences (NASDAQ:WVE) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Do analysts rate WVE or ESPR? Wave Life Sciences currently has a consensus price target of $22.18, suggesting a potential upside of 253.21%. Esperion Therapeutics has a consensus price target of $6.58, suggesting a potential upside of 561.18%. Given Esperion Therapeutics' higher probable upside, analysts plainly believe Esperion Therapeutics is more favorable than Wave Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer WVE or ESPR? In the previous week, Wave Life Sciences had 13 more articles in the media than Esperion Therapeutics. MarketBeat recorded 18 mentions for Wave Life Sciences and 5 mentions for Esperion Therapeutics. Wave Life Sciences' average media sentiment score of 0.80 beat Esperion Therapeutics' score of 0.68 indicating that Wave Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Wave Life Sciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is WVE or ESPR more profitable? Esperion Therapeutics has a net margin of -29.37% compared to Wave Life Sciences' net margin of -66.50%. Esperion Therapeutics' return on equity of 0.00% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Wave Life Sciences-66.50% -280.57% -52.90% Esperion Therapeutics -29.37%N/A -10.77% Which has more risk and volatility, WVE or ESPR? Wave Life Sciences has a beta of -0.93, suggesting that its share price is 193% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Does the MarketBeat Community favor WVE or ESPR? Esperion Therapeutics received 261 more outperform votes than Wave Life Sciences when rated by MarketBeat users. Likewise, 70.25% of users gave Esperion Therapeutics an outperform vote while only 67.84% of users gave Wave Life Sciences an outperform vote. CompanyUnderperformOutperformWave Life SciencesOutperform Votes36767.84% Underperform Votes17432.16% Esperion TherapeuticsOutperform Votes62870.25% Underperform Votes26629.75% Which has stronger valuation and earnings, WVE or ESPR? Wave Life Sciences has higher earnings, but lower revenue than Esperion Therapeutics. Wave Life Sciences is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWave Life Sciences$108.30M8.90-$57.51M-$0.79-7.95Esperion Therapeutics$332.31M0.59-$209.25M-$0.25-3.98 Do insiders and institutionals hold more shares of WVE or ESPR? 89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by insiders. Comparatively, 1.0% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryEsperion Therapeutics beats Wave Life Sciences on 10 of the 19 factors compared between the two stocks. Remove Ads Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$197.00M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio-1.566.7921.7317.81Price / Sales0.59225.93379.1994.60Price / CashN/A65.6738.1534.64Price / Book-0.265.866.464.00Net Income-$209.25M$141.86M$3.20B$247.23M7 Day Performance-6.07%8.98%6.54%7.26%1 Month Performance-33.62%-12.65%-8.55%-6.26%1 Year Performance-48.54%-11.99%10.33%-0.18% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics3.654 of 5 stars$1.00-0.3%$6.58+561.2%-48.5%$197.00M$332.31M-1.56200WVEWave Life Sciences4.1709 of 5 stars$5.78-4.2%$22.60+291.3%+9.4%$886.38M$108.30M-5.20240Short Interest ↑Analyst RevisionCOLLCollegium Pharmaceutical4.0797 of 5 stars$27.37-2.7%$43.60+59.3%-22.8%$879.58M$631.45M11.80210Positive NewsGap DownELVNEnliven Therapeutics2.5632 of 5 stars$17.82-4.7%$38.75+117.5%-14.5%$873.06MN/A-9.3850News CoverageDYNDyne Therapeutics3.5747 of 5 stars$7.48-9.6%$47.46+534.3%-69.1%$846.37MN/A-2.10100GPCRStructure Therapeutics2.5757 of 5 stars$14.33-5.2%$81.29+467.4%-49.8%$821.55MN/A-19.36136News CoverageCMRXChimerix2.9082 of 5 stars$8.53-0.1%$8.53+0.1%+834.8%$799.68M$212,000.00-9.0790ETNB89bio2.5885 of 5 stars$5.48-5.1%$27.56+403.3%-36.2%$799.26MN/A-1.8840Short Interest ↑News CoverageHigh Trading VolumeCDMOAvid Bioservices0.7966 of 5 stars$12.50+0.1%$12.25-2.0%+83.8%$799.18M$139.91M-5.23320High Trading VolumeRCUSArcus Biosciences2.4498 of 5 stars$7.28+5.9%$30.25+315.8%-50.9%$764.88M$258M-2.31500VIRVir Biotechnology2.6735 of 5 stars$5.53-1.0%$35.67+545.6%-34.4%$757.72M$63.71M-1.41580Short Interest ↑ Remove Ads Related Companies and Tools Related Companies Wave Life Sciences Competitors Collegium Pharmaceutical Competitors Enliven Therapeutics Competitors Dyne Therapeutics Competitors Structure Therapeutics Competitors Chimerix Competitors 89bio Competitors Avid Bioservices Competitors Arcus Biosciences Competitors Vir Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESPR Stock Free ESPR Stock Alerts